Abstract
Phosphofructokinase deficiency (Tarui disease, glycogen storage disease VII, GSD VII) stands out among all the GSDs. PFK deficiency was the first recognized disorder that directly affects glycolysis. Ever since the discovery of the disease in 1965, a wide range of biochemical, physiological and molecular studies of the disorder have greatly expanded our understanding of the function of normal muscle, general control of glycolysis and glycogen metabolism. The studies of PFK deficiency vastly enriched the field of glycogen storage diseases, as well as the field of metabolic and neuromuscular disorders. This article cites a historical overview of this clinical entity and the progress that has been made in molecular genetic area. We will also present the results of a search in-silico, which allowed us to identify a previously unknown sequence of the human platelet PFK gene (PFK-P). In addition, we will describe phylogenetic analysis of evolution of PFK genes.
Keywords: phosphofructokinase deficiency, tarui disease, glycogen storage disease Vll(gsd Vll)
Current Molecular Medicine
Title: Phosphofructokinase Deficiency Past, Present and Future
Volume: 2 Issue: 2
Author(s): Hiromu Nakajima, Nina Raben, Tomoya Hamaguchi and Tomoyuki Yamasaki
Affiliation:
Keywords: phosphofructokinase deficiency, tarui disease, glycogen storage disease Vll(gsd Vll)
Abstract: Phosphofructokinase deficiency (Tarui disease, glycogen storage disease VII, GSD VII) stands out among all the GSDs. PFK deficiency was the first recognized disorder that directly affects glycolysis. Ever since the discovery of the disease in 1965, a wide range of biochemical, physiological and molecular studies of the disorder have greatly expanded our understanding of the function of normal muscle, general control of glycolysis and glycogen metabolism. The studies of PFK deficiency vastly enriched the field of glycogen storage diseases, as well as the field of metabolic and neuromuscular disorders. This article cites a historical overview of this clinical entity and the progress that has been made in molecular genetic area. We will also present the results of a search in-silico, which allowed us to identify a previously unknown sequence of the human platelet PFK gene (PFK-P). In addition, we will describe phylogenetic analysis of evolution of PFK genes.
Export Options
About this article
Cite this article as:
Nakajima Hiromu, Raben Nina, Hamaguchi Tomoya and Yamasaki Tomoyuki, Phosphofructokinase Deficiency Past, Present and Future, Current Molecular Medicine 2002; 2 (2) . https://dx.doi.org/10.2174/1566524024605734
DOI https://dx.doi.org/10.2174/1566524024605734 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets The Role of Peroxidation of Mitochondrial Membrane Phospholipids in Pancreatic β -Cell Failure
Current Diabetes Reviews Role of Statins in New-onset Diabetes Mellitus: The Underlying Cause, Mechanisms Involved, and Strategies to Combat
Current Drug Targets The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases
Current Medicinal Chemistry Editorial [Hot Topic: Rising of Phosphatases as Targets of Cancer Treatment (Guest Editor: Petr Heneberg)]
Anti-Cancer Agents in Medicinal Chemistry Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists
Current Vascular Pharmacology Recent Advances on Detection of Modified Forms of Low-Density Lipoproteins
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases
Current Stem Cell Research & Therapy Proteomic Profiling of Maternal Serum for Early Risk Analysis of Preterm Birth
Current Proteomics Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats
Protein & Peptide Letters Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Transcriptional Regulation of the Heme Oxygenase-1 Gene Via the Stress Response Element Pathway
Current Pharmaceutical Design Sphingolipids in Genetic and Acquired Forms of Chronic Kidney Diseases
Current Medicinal Chemistry Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry Quantitative Analysis of Metformin with Special Emphasis on Sensors: A Review
Current Analytical Chemistry Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets